.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Deloitte
Julphar
QuintilesIMS
Accenture
Queensland Health
Chinese Patent Office
Boehringer Ingelheim
Healthtrust
Baxter

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,251,910

« Back to Dashboard

Which drugs does patent 6,251,910 protect, and when does it expire?


Patent 6,251,910 protects BRILINTA and is included in one NDA. There have been two Paragraph IV challenges on Brilinta.

This patent has forty-four patent family members in thirty-four countries.

Summary for Patent: 6,251,910

Title: 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Abstract:Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
Inventor(s): Guile; Simon (Loughborough, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (Nottingham, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:09/155,023
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo6,251,910► SubscribeY
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes6,251,910► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,251,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702773Jul 22, 1997
PCT Information
PCT FiledJuly 15, 1998PCT Application Number:PCT/SE98/01393
PCT Publication Date:February 04, 1999PCT Publication Number: WO99/05143

International Patent Family for Patent: 6,251,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia996621► Subscribe
Sweden9702775► Subscribe
Sweden9702773► Subscribe
Saudi Arabia1153► Subscribe
Russian Federation2225407► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
US Army
US Department of Justice
Accenture
Moodys
Harvard Business School
Teva
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot